- CDC
- Heart Failure
- Cardiovascular Clinical Consult
- Adult Immunization
- Hepatic Disease
- Rare Disorders
- Pediatric Immunization
- Implementing The Topcon Ocular Telehealth Platform
- Weight Management
- Screening
- Monkeypox
- Guidelines
- Men's Health
- Psychiatry
- Allergy
- Nutrition
- Women's Health
- Cardiology
- Substance Use
- Pediatrics
- Kidney Disease
- Genetics
- Complimentary & Alternative Medicine
- Dermatology
- Endocrinology
- Oral Medicine
- Otorhinolaryngologic Diseases
- Pain
- Gastrointestinal Disorders
- Geriatrics
- Infection
- Musculoskeletal Disorders
- Obesity
- Rheumatology
- Technology
- Cancer
- Nephrology
- Anemia
- Neurology
- Pulmonology
5 Obesity Drugs Worth Watching: 2024-2025
Incretin analogues, an oral glucose formulation that targets endogenous nutrient-sensing pathways and a cannabinoid receptor 1 antagonist are in the new mix.
Incretin analogues predominate among the 5 investigational weight management drugs highlighted in this slide show but an oral glucose formulation that targets endogenous nutrient-sensing pathways and a cannabinoid receptor 1 antagonist are delivering commensurate results.
Development of medications to manage the metabolic dysregulation that drives overweight and obesity has become a bit of a blood sport, with hundreds of companies vying to deliver the next most effective molecule or combination of molecules that will modify the underlying pathology while producing negligible, or at least minimal, adverse effects.
Topline data for most of the 5 agents discussed in this slide show have been presented at professional society meetings over the past year and the companies behind them plan new readouts either late this year or in early-mid 2025. Information for the slide show was culled from the BioSpace website as well as manufacturer news.
